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The detergents used to solubilize GPCRs can make crystal growth the rate-limiting step in determining
their structure. The Kobilka laboratory showed that insertion of T4-lysozyme (T4L) in the 3rd
intracellular loop is a promising strategy towards increasing the solvent-exposed receptor area, and
hence the number of possible lattice-forming contacts. The potential to use T4L with the olfactory-
related receptors hOR17-4 and hVN1R1 was thus tested. The structure and function of native and
T4L-variants were compared. Both receptors localized to the cell membrane, and could initiate
ligand-activated signaling. Purified receptors not only had the predicted alpha-helical structures, but
also bound their ligands canthoxal (MW = 178.23) and myrtenal (MW = 150.22). Interestingly, the
T4L variants had higher percentages of soluble monomers compared to protein aggregates, effectively
increasing the protein yield that could be used for structural and function studies. They also bound
their ligands for longer times, suggesting higher receptor stability. Our results indicate that a T4L
insertion may be a general method for obtaining GPCRs suitable for structural studies.
Introduction
Althoughmembrane proteins comprise 20–30%of cellular proteins
and have significant biological importance, membrane protein
research lags far behind that of soluble proteins.1,2 Knowledge
about GPCRs in particular is sparse. This is due primarily to
the difficulty in determining their structure. As of October
2011, over 76 000 protein structures have been determined.
Only 303 are unique membrane proteins. Of these, only 7 are
GPCRs (http://www.pdb.org/pdb/home/home.do).
GPCRs are difficult to crystallize for four main reasons.
First, abundant quantities of protein are needed to set up
crystallization trials, but most are endogenously expressed at
low levels. Only rhodopsin, the first crystallized GPCR, is
easily obtained in sufficient quantities from native tissues.
Second, suitable methods must be found to extract, solubilize,
and purify GPCRs. Third, GPCRs must be functionally
stabilized for long periods of time, as protein crystals can take
weeks or even months to grow. Because GPCRs have a
hydrophobic transmembrane region bounded by hydrophilic
ends, they aggregate and precipitate out of aqueous solutions
when removed from their native membrane environment.
Detergents that mimic the lipid bilayer must therefore be used
to maintain GPCRs in a stable, non-aggregated form. Fourth,
the flexible nature of GPCRs, and the materials used to
stabilize them in aqueous environments, can inhibit crystal
lattice formation. Each bottleneckmust be sequentially overcome.
However, no universal method exists: optimal protocols for
expression, purification, solubilization, and crystal growth must
be empirically determined for each protein of interest.2
The last bottleneck is usually the rate-limiting step, as the
difficulty in predicting crystal growth conditions necessitates
screening through thousands of possibilities. Several strategies
have been developed to facilitate membrane protein crystal
growth.3–10 To increase the surface area available to form a crystal
lattice, T4-lysozyme (T4L) fusions have been synthesized,3–8 and
antibody fragments against specific portions of the membrane
protein have been used.9 These antibody or T4L fragments are
soluble proteins that effectively increase the solvent-exposed
receptor area, thereby facilitating protein–protein contacts
needed for crystal formation. To increase the structural homo-
geneity of a protein sample, loops and other large protein
segments without a defined and stable secondary structure
have been deleted, and post-translational modifications like
glycosylation have been removed.3–5,7–10 To improve protein
stability, sequence mutations have been introduced.4,6,10
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Current strategies are rationally designed, but must be
empirically tested with each membrane protein. The most
beneficial strategy in membrane protein structural research
would be the one that could be used with many proteins.
Insertion of T4L in the third intracellular loop seems to be a
promising technique for GPCRs, as five of the seven crystallized
GPCRs used this approach.3–9 Unlike the development of antibody
fragments, generation of DNA templates is fast using current
cloning techniques, and many templates can easily be generated
in parallel. This method also allows the entire protein or the
majority of it to be crystallized. However, insertion of T4L
near the putative G-protein binding domain can disrupt
receptor function. It can also potentially interfere with proper
folding, limiting the useful information that could be obtained
from the crystal structure. It is thus necessary to evaluate how a
T4L insert can affect the structure and function of various GPCRs.
This study examines the ability of T4L to be used as a
general insert in olfactory-related GPCRs. Two GPCRs were
chosen: hOR17-4 and hVN1R1. These receptors belong to two
of the four families of GPCRs involved in olfaction. Structural
knowledge of these different families can elucidate the different
roles they play. Moreover, both receptors are expressed in
other tissues, indicating non-olfactory functions as well.11,12
Native and T4L-variants of hOR17-4 and hVN1R1 were
expressed in HEK293 cells. The structure and function of
the T4L variants were compared to the native forms. Immuno-
cytochemistry showed that both protein forms were localized to the
cell surface; and calcium imaging suggested that they could initiate
second messenger signaling upon activation by their specific
agonist. Circular dichroism analyses of purified receptors showed
that the native and T4L-variants had alpha-helical structures.
Microscale thermophoresis showed that the purified receptors
bound their small molecule ligands canthoxal and myrtenal.
Interestingly, the T4L-variants yielded higher percentages of
soluble monomers compared to aggregates, indicating that the
T4L insert stabilized the protein structure. These T4L variants
also had lower ligand-binding affinities, but yielded more
consistent binding results over time with less noise, thus
suggesting longer receptor stability. These results suggest that
a T4L insertion may be a general method when working with
GPCRs and other 7-transmembrane proteins (7TM).
Materials and methods
hOR17-4T4L and hVN1R1-T4L gene design and construction
The protein sequences for hOR17-4 (NCBI Accession
#NP002539) and hVN1R1 (AAG10698) were obtained from
GenBank. To enable expression and purification from mammalian
cells, the following modifications were made to both genes: (1)
addition of a C-terminal rho tag (TETSQVAPA) preceded by a
two glycine linker; (2) human codon optimization; (3) addition of a
Kozak sequence 50 to the start codon; (4) addition of a 50 EcoRI
site and a 30 XhoI site to facilitate subcloning into expression
vectors; (5) addition of an N-terminal strep tag (ASWSHPQFEK)
followed by a GSSG linker for further purification; (6) insertion of
T4 lysozyme residues 2-161 in the predicted third intracellular loop
after residue S232 in hOR17-4 and after residue L261 in hVN1R1;
and (7) N5Q and N195Q mutations in hOR17-4, and N117Q,
N151Q, N183Q, N198Q, and N256Q mutations in hVN1R1 to
facilitate crystallization. The genes were constructed by Geneart
and ligated into the pcDNA4/To vector (Invitrogen, Carlsbad,
CA). The plasmids were amplified in subcloning efficiency
DH5a E. coli (Invitrogen) and purified using MiniPrep or
MaxiPrep kits (Quiagen, Valencia, CA). The transmembrane
and loop domains were predicted using the TMHMM Server v
2.0 (http://www.cbs.dtu.dk/services/TMHMM/). The DNA
sequences for hOR17-413 and hVN1R114 were synthesized as
previously described.
Construction of stable inducible HEK293 cell lines
The generation of stable, inducible cell lines capable of
expressing the desired proteins is described in ref. 11–13.
Briefly, HEK293S N-acetylglucosaminyltransferase I-negative
cells (HEK293G) containing the pcDNA6/Tr vector were
transfected with the pcDNA4/To hVN1R1 vector using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Forty-eight hours after transfection, selective media
containing 5 mg ml1 of blasticidin and 50 mg ml1 zeocin were
added. Cells were re-seeded at low density and grown until
individual colonies formed. Colonies were picked and screened
for inducible receptor expression. Cells were treated with plain
media, media supplemented with 1 mg ml1 tetracycline, andmedia
supplemented with 1 mg ml1 tetracycline and 2.5 mM sodium
butyrate. Two days after induction, cells were scrape-harvested and
solubilized in PBSwith 2%w/v Fos-Choline 14 (FC-14) (Anatrace)
and protease inhibitors (Roche #04693132001) for 1 h at 4 1C.
Cell lysates were centrifuged for 30 minutes at 10 000 rpm to
remove insoluble debris. Dot blots and Western-blots were
used to compare protein expression among clones. The clone
with the highest expression when induced, the least detectable
expression when not induced, and least toxicity upon induction,
was expanded for future experiments. All cultures were grown in
DMEM F12 with GlutaMAX (Invitrogen #10565-042) supple-
mented with 10% fetal bovine serum (Invitrogen #16000-044),
15 mMHEPES (Invitrogen), 0.1 mM non-essential amino acids
(Invitrogen), 0.5 mM sodium pyruvate (Invitrogen), 100 units
per ml penicillin and 100 mg ml1 streptomycin (Invitrogen).
The expanded stable clones were maintained in media that also
contained 5 mg ml1 blasticidin and 25 mg ml zeocin1. All cells
were grown at 37 1C, 5% CO2, and 95% relative humidity.
Western blotting and silver staining
Western blots and silver stains were used to detect proteins
and analyze their purity. Samples were prepared and loaded in
Novex 10% Bis-Tris SDS-PAGE gels (Invitrogen) according
to the manufacturer’s protocol, with the exception that the
samples were incubated at room temperature prior to loading
as boiling causes membrane protein aggregation. For blotting,
the gel-resolved samples were transferred to a nitrocellulose
membrane, blocked in milk (5% w/v non-fat dried milk in
TBST) for 1 hour, and incubated with a rho1D4 primary
antibody (Cell Essentials, 1.58 mg ml1 stock, 1 : 3000 in
TBST, 1 hour at room temperature, or overnight at 4 1C).
The GPCRs were then detected with a goat anti-mouse
HRP-conjugated secondary antibody (Pierce, Rockford, IL)
(1 : 5000 in TBST, 1 hour, room temperature) and visualized
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using the ECL-Plus Kit (GE Healthcare). The SilverXpress kit
(Invitrogen, LC6100) was used according to the manufacturer’s
instructions to perform total protein stains of the samples. All
images were captured using a Fluor Chem gel documentation
system (Alpha Innotech, San Leandro, CA).
Immunocytochemistry
Receptors were visualized using a rho1D4 primary antibody.
Cells were seeded at low density on poly-L-lysine (Sigma-Aldrich)
coated glass coverslips. After one day, cells were induced with
1 mg ml1 tetracycline and 1 mM sodium butyrate. One day
after induction, the media was removed. Cells were gently
washed with PBS and fixed for 20 minutes in 10% neutral
buffered formalin (Sigma-Aldrich) at room temperature.
Permeabilized (1 : 1 acetone : methanol, 3 minutes, 20 1C)
and non-permeabilized cells were then blocked in PBST (PBS,
0.2% Tween-20, 0.3 M glycine, 4% serum) for 1 hour at room
temperature, and incubated with the primary antibody solution
(1.58 mg ml1 stock, 1 : 1000, PBS, 0.2% Tween-20, 4% serum)
overnight at 4 1C. The labeled protein was visualized with
Alexa-flour-488 goat-anti-mouse secondary antibody conjugate
(1 : 3000, PBS, 1 hour, room temperature). Slides were
mounted using ProLong Gold Antifade with DAPI. A Nikon
Plan Apo 60x oil immersion lens was used.
Ca2+ imaging
HEK293 cells expressing hOR17-4 or hOR17-4T4L were
seeded on 0.18 mm thick cover-glass slides at a density of
105 cells ml1. OR expression was induced with 1 mg ml1 of
tetracycline for 48 h. To visualize calcium signaling, cells were
loaded with 10 mM Fura-Red-AM (Invitrogen) for 30 min in
serum-free DMEM/F12 medium and washed in PBS. The cells
were then incubated an additional 30 min in DMEM/F12
supplemented with 10%FCS to allow intracellular Fura-Red-AM
to completely hydrolyze. Ca2+ signaling in response to 50 mM of
the odorant bourgeonal was visualized using confocal fluorescence
microscopy (Zeiss LSM 510) with a water immersion objective
(Zeiss Achroplan 63x NA 1.2). The cells were excited at 488 nm
(Ar + laser), and fluorescence emission of Fura-Red-AM was
monitored at 650 nm using a long pass emission filter. Images were
collected every 2 seconds for a total of 100 seconds. ATP was used
as a control. Unless noted otherwise, cells were incubated at 37 1C
and 5% CO2 in DMEM (Dulbecco’s modified Eagle’s medium,
Invitrogen, San Diego, CA) supplemented with 10% FCS
(Invitrogen). Calcium imaging of hVN1R1 and hVN1R1-T4L
cells was not performed due to the higher toxicity of expressing
the proteins, and because it is not known whether the receptors
are capable of coupling to the endogenous HEK293 G-proteins.16
Cell extract preparation
Cells were grown on plates as previously described.13,14 When
the appropriate density was reached, cells were induced with
tetracycline and sodium butyrate. After two days, cells were
scrape harvested. They were pooled, and either used immediately,
or snap-frozen in liquid nitrogen and stored at 80 1C until used
for future experiments.
Detergent screening
Frozen cell pellets were thawed on ice and resuspended in PBS
containing protease inhibitors (Roche). Detergents were added
to a final concentration of 2% w/v. The suspensions were
rotated for 1 hour at 4 1C to solubilize the protein, and were
spun at 13 000 rpm for 30 minutes to remove insoluble
fractions. Relative protein solubilization in each detergent
was assayed with a dot blot. Ninety-six detergents were
selected for screening as previously described.17
Receptor purification
Rho1D4 immunoaffinity purification has been previously
described.13–15 Briefly, frozen cell pellets were thawed on ice.
Cells were resuspended in PBS containing protease inhibitors.
PBS containing FC-14 was added to a final concentration of
2% w/v FC-14. The final liquid : cell ratio was 12.5 ml/1 g cells.
The protein was solubilized by rotating for 4 hours at 4 1C. The
non-solubilized fraction was pelleted by centrifuging for 30 minutes
at 30 000g at 4 1C. The solubilized fraction was incubated with
DNAse (1 : 2000) and RNAse (1 : 1000) for 15 minutes on
ice. Rho1D4-coupled CNBr-activated Sepharose 4B beads
(GE Healthcare) were added to the cell extract supernatant
(binding capacity 0.7 mg ml1); receptors were captured by
rotating the mixture overnight at 4 1C. The beads were
collected by centrifuging at 1400 rpm for 1 minute, or filtering
the supernatant through a filter column (Biorad). The supernatant
was saved for future analysis and labeled as ‘‘flow-through’’.
The beads were resuspended in 1 bead volume of wash buffer
(PBS + 0.2% w/v FC-14), rotated for 10 minutes at 4 1C, and
re-pelleted. Washes were performed until the total protein
concentration in the washes was less than 0.01 mg ml1
(NanoDrop). One bead volume of elution buffer (PBS + 0.2%
w/v FC-14 + 800 mMAc-TETSQVAPA-NH2 peptide) was then
added to the beads. Elutions were performed until the total
protein concentration was less than 0.01 mg ml1.
Size exclusion chromatography was used to separate the
monomeric and higher molecular-weight forms of the receptor. A
Hi-Load 16/60 Supradex 200 column with a A¨kta Purifier HPLC
system (GE Healthcare) was used. The column was first equili-
brated with at least 1 column volume of wash buffer. Protein
samples were concentrated to 1.5–3 ml using a 50000 MWCO
filter column (Millipore), loaded on the column, and run with
wash buffer at 0.3 ml min1. Fractions exiting the column were
automatically collected; the protein content was monitored with
UV absorbance at 215 nm, 254 nm, and 280 nm. Peak fractions
were pooled, concentrated, and analyzed with Western blotting
and silver staining (SilverXpress, Invitrogen).
Secondary structure analysis using circular dichroism
CD spectra were measured over the wavelengths 200 nm–350 nm
with a CD spectrometer (AVIV Biomedical Model 202).
Measurements were made at 15 1C, with a step size of 1 nm
and an averaging time of 4 seconds. Measurements for each
sample were made in triplicate and averaged. The protein
spectra were blanked to the spectrum obtained for wash
buffer. A QS quartz cuvette (Hellma) with a 1 mm path length
was used to perform all experiments.
Pu
bl
ish
ed
 o
n 
15
 M
ar
ch
 2
01
2.
 D
ow
nl
oa
de
d 
by
 L
ud
w
ig
 M
ax
im
ili
an
s U
ni
ve
rs
ita
et
 M
ue
nc
he
n 
on
 1
1/
07
/2
01
3 
11
:0
9:
08
. 
View Article Online
This journal is c The Royal Society of Chemistry 2012 Mol. BioSyst., 2012, 8, 1750–1759 1753
Ligand binding measurements
Microscale thermophoresis was used to measure the binding
interactions between purified receptors and their ligands using
a setup similar to that previously described.18–20 To eliminate
artifacts caused by labeling or modifying proteins, the fluores-
cence of native GPCR tryptophans was used to monitor the
local receptor concentration. For each sample, a titration
series with constant receptor concentration and varying ligand
concentrations was prepared in a final solution of 10%DMSO
and 0.2% FC-14 in PBS. Potential autofluorescence of each
ligand was checked: no fluorescence signal was detected from
the ligands in the tryptophan fluorescence channel. The final
receptor concentration was 1–2 mM. Approximately 1.5 ml of
each sample was loaded in a fused silica capillary (Polymicro
Technologies, Phoenix, USA) with an inner diameter of 300 mm.
An infrared laser diode was used to create a 0.12 K mm1
temperature gradient inside the capillaries (Furukawa FOL1405-
RTV-617-1480, wavelength l = 1480 nm, 320 mW maximum
power, AMS Technologies AG, Mu¨nich Germany). Tryptophan
fluorescence was excited with a UV-LED (285 nm), and was
measured with a 40 SUPRASIL synthetic quartz substrate
microscope objective, numerical aperture 0.8 (Partec, Goerlitz,
Germany). The local receptor concentration in response to the
temperature gradient was detected with a photon counter
PMT P10PC (Electron Tubes Inc, Rockaway, NJ, USA).
All measurements were performed at room temperature.
Fluorescence filters for tryptophan (F36-300) were purchased
from AHF-Analysentechnik (Tu¨bingen, Germany).
Results
Induction of hOR17-4T4L and hVN1R1-T4L expression in
stable HEK293 cell lines
The native forms of hOR17-4 and hVN1R1 were previously
expressed.13–15 The T-Rex system was used to make the T4L
variants in the same manner as the native receptors. Final
induction conditions for hOR17-4T4L were 1 mg ml1 of
tetracycline with 5 mM sodium butyrate, and for hVN1R1
were 1 mg ml1 of tetracycline with 1 mM sodium butyrate. All
inductions were performed for 48 hours prior to harvesting the
cells for receptor purification. The expressed protein was
analyzed using SDS-PAGE and Western blotting. Both T4L
clones had two bands, corresponding to the monomeric and
dimeric forms of the receptor (Fig. 1). The presence of this
characteristic size pattern indicates that the T4L insert does
not significantly alter receptor folding or function, as both
GPCRs are capable of forming dimers.
Immunohistochemical staining of induced cells
GPCRs often become trapped in the cell when expressed in
heterologous systems. This is particularly true when post-
translational modifications like glycosylation are removed,
suggesting that the conserved N-terminal glycosylation site
of ORs may be necessary for appropriate localization.21–27 To
determine whether the stably expressed hOR17-4T4L or
hVN1R1-T4L receptors were trafficked to the cell membrane,
induced and non-induced cells were stained with the rho1D4
antibody (Fig. 2). Non-induced cells yielded no signal, while
induced cells showed receptors that were localized to the cell
membrane. Permeabilized and non-permeabilized cells both
demonstrated membrane localization, suggesting that not all
receptors are inserted in the correct orientation. However,
visualization of both native and T4L-variants in the
membrane suggests that the T4L insert did not affect GPCR
trafficking. The results also suggest that the glycosylation sites
are not necessary for localization of the protein to the
membrane.
Functional characterization of hOR17-4T4L in HEK293 cells
The functional activity of hOR17-4T4L was probed by measuring
intracellular Ca2+ signaling in response to the specific odorant
bourgeonal.12,28 In HEK293 cells, hOR17-4, like other olfactory
receptors, can couple to the promiscuous G protein Gaq to initiate
a signal through the inositol triphosphate (IP3) pathway.
13,15,29
Similar results were observed with hOR17-4T4L: application of
50 mM bourgeonal resulted in a transient increase in intracellular
Ca+2 concentration (Fig. 3). However, this Ca+2 response
was 60–70% lower than the native protein. Also, the time
needed to return to baseline Ca+2 levels after induction was
shorter (5–10 seconds for hOR17-4T4L, and 25 seconds for
hOR17-4). These results show that hOR17-4T4L is capable of
signal transduction, although in a reduced capacity. The
receptors hVN1R1 and hVN1R1-T4L were not tested due to
the higher levels of cell toxicity after expression.
Systematic detergent screening for receptor solubilization
An appropriate detergent must be used to solubilize receptors
from cell membranes, and keep them stable and functional in
solution. A confounding factor is that different detergents may
need to be used even for similar or related proteins, and must
therefore be empirically determined. Thus, although optimal
detergents for hOR17-4 and hVN1R1 have been experimentally
Fig. 1 Expression of hOR17-4T4L and hVN1R1-T4L in HEK293
cells. (A) Western blot of hOR17-4T4L, and (B) Western blot of
hVN1R1-T4L solubilized from HEK293 cells using FC-14. Lane 1
shows receptor solubilized from uninduced cells, lane 2 shows receptor
solubilized from cells induced with 1 mg ml1 of tetracycline for
48 hours, and lane 3 shows receptor solubilized from cells induced
with 1 mg ml1 of tetracycline and 5 mM sodium butyrate for 48 hours.
No protein was detected in uninduced cells. Induction with tetra-
cycline and sodium butyrate resulted in maximum expression. Both
receptors had monomeric and dimeric forms. Subsequent experiments
determined that the optimal sodium butyrate concentration was 5 mM
for hOR17-4T4L, and 1 mM for hVN1R1-T4L.
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determined,13,14 new detergent screens were performed for
hOR17-4T4L and hVN1R1-T4L.
The optimal detergents for hVN1R1-T4L and hOR17-4T4L
were again the fos-choline series (Table 1). The receptors
hVN1R1, hVN1R1-T4L, and hOR17-4 had nearly identical
detergent profiles, which were also similar to the profiles
reported for several other GPCRs.14,17 In contrast, hOR17-4T4L
exhibited a slightly different profile. For hVN1R1, hVN1R1-T4L,
and hOR17-4, receptor solubility was vastly improved in
the fos-choline detergents compared to most of the other
detergents. Only a handful of other detergents were able to
solubilize comparable amounts of protein. While receptor
solubility for hOR17-4T4L was higher in the fos-cholines than
in any other detergent class, many other detergents were able
to solubilize sufficient quantities of receptor. The cyclo-fos and
anzergent families yielded only slightly less soluble protein
than the fos-cholines, as well as Fos-MEA-10 and FOSFEN-9.
This similarity is not surprising, as these detergents have similar
structures. The only difference between the fos-cholines and
cyclofos detergents is a cyclohexane ring at the end of the
cyclofos carbon chain. Similarly, FOSFEN detergents have a
phenyl ring attached to the carbon chain. Fos-MEA detergents
are similar to the fos-cholines, except that 2 methyl groups on
Fig. 2 Immunohistochemical staining of native and T4L clones. (A)
Uninduced hVN1R1; (B) induced hVN1R1; (C) uninduced hVN1R1-
T4L; (D) induced hVN1R1-T4L; (E) uninduced hOR17-4; (F) induced
hOR17-4; (G) uninduced hOR17-4T4L; (H) induced hOR17-4-T4L.
The noninduced cells express undetectable amounts of receptor. The
expressed receptors are localized to the cell membranes. Panel E was
overexposed to visualize the cells; some leaky expression can be seen in
a few cell membranes, but otherwise no surface-localization can be
seen. (A) and (B) are from ref. 14, and are shown here for comparison.
Fig. 3 Ca+2 imaging profiles for (A) hOR17-4T4L and (B) hOR17-4
expressed in stable, inducible HEK293 cells. Responses from three
individual cells (nos. 1, 2, 3) are shown for hOR17-4T4L, and two
individual cells (nos. 1, 2) for hOR17-4. The intracellular Ca+2
concentration was monitored with confocal microscopy using
Fura-Red as an indicator. The intensities are displayed in pseudo
color (A and B, top). The cytosolic Ca+2 concentration is recorded as
a function of time (A and B, bottom). The arrows indicate the times at
which, initially the odorant bourgeonal, and subsequently ATP were
applied. 100 mM ATP was used as a control for cell viability. The
profiles show that both proteins initiate signal transduction, though
the response from hOR17-4T4L is lower in amplitude and shorter in
duration. The size bar is 10 mm.
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the choline nitrogen have been replaced with hydrogens. The
anzergents exhibit slightly greater differences: they have a sulfate
group instead of a phosphate group, and the order of the
negatively and positively charged groups is reversed. All of these
Table 1 Detergent solubilization of hVN1R1, hVN1R1-T4L, hOR17-4, and hOR17-4T4L*
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detergents are structurally or chemically similar to phosphatidyl-
cholines, phospholipids that are major constituents of cell
membranes. Thus, although hOR17-4T4L has a different
detergent profile than the other tested GPCRs, these results
reinforce increasing evidence that detergents that are structurally
related to biological phospholipids are optimal detergents for
GPCRs. It should be noted that several other detergents, including
the maltosides, were able to solubilize noticeable amounts of
protein. However, they were not as effective as the fos-cholines
or related detergents.
Purification of hOR17-4T4L and hVN1R1-T4L
A two-step purification procedure using immunoaffinity
chromatography and size-exclusion chromatagraphy (SEC)
was used to purify the expressed receptors.13–15 While UV
absorption at 280 nm typically showed three distinct peaks for
the native proteins, it usually showed only two for the T4L
variants. Western blot analysis demonstrated that the three
native peaks corresponded to aggregated, dimerized, and
monomeric forms of the protein.13,14 Similar analyses of the
T4L-variants showed that the peaks corresponded to dimerized
and monemeric protein forms (Fig. 4). There was little or no
evidence of aggregated receptor. The UV readings also indicated
that a higher percentage of the total protein obtained was a
soluble monomer. These results suggest that the T4L insert may
help stabilize the receptor in a soluble state, and that a higher
proportion of protein purified from a T4L-variant batch will be
usable for crystallization screens. Both native and T4L-variant
proteins were able to yield about 1 mg of total protein per gram
of cells. However, depending on the purification batch, at least
50% and up to 60–70% of the protein recovered after SEC was
the soluble monomer for the T4L variants. In contrast,
typically B10–40% of the protein recovered after SEC was
the soluble monomer for the native ones.
Structural characterization of purified hOR17-4T4L and
hVN1R1-T4L
The secondary structure of the T4L variants was assayed using
circular dichroism (CD). Far UV spectra of both proteins
have characteristic alpha-helical spectra, similar to the native
proteins (Fig. 5). However, the peaks at 208 nm and 220 nm
are more defined in the T4L variants. A CD spectrum is
assumed to be a linear composition of the individual spectra
of each secondary structure present in the tested protein.
A protein that is purely alpha-helical in shape will have sharply
defined peaks at 208 nm and 220 nm, while a protein that has a
higher percentage of loops and random coils will have peaks
that are less pronounced.30 These results thus suggest that the
T4L insert may help to structurally stabilize the proteins.
Ligand binding analysis of purified hOR17-4T4L and hVN1R1-T4L
Microscale thermophoresis (MST) was used to determine
whether the native proteins and T4L variants could bind their
ligands. Microscale thermophoresis is a technique that induces
a local spatial temperature gradient. Proteins in the gradient
migrate along it. Free receptors have a different migration
speed compared to receptors that are bound to their ligands,
likely due to changes in their hydration shell.18,31 MST can
measure binding of ligands as small as individual ions,19 which
is critical because odorants are less than 300 Da while their
receptors are larger than 30 kDa. MST can also be used in
receptors in solution, and can detect fluorescence from native
Fig. 4 280 nm UV traces through a size exclusion column and a silver stain of the T4L fractions. (A) Typical 280 nm UV trace of hVN1R1,
(B) typical 280 nm UV trace of hOR17-4, (C) typical 280 nm UV trace of hVN1R1-T4L, (D) typical 280 nm UV trace of hOR17-4T4L, and
(E) silver stain of the purified samples in (C) and (D). Peak 1 from (D) is not shown, but contained primarily aggregated protein. The native
proteins yield more aggregated receptors. The T4L variants are primarily a monomeric population. This suggests that the T4L insert prevents
aggregation by keeping the receptors soluble in the monomeric or, secondarily, dimerized state. Number code: (1) aggregate; (2) dimer;
(3) monomer. Blots of peak fractions in (A) and (B) have been reported in ref. 14 and 15.
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tryptophans, thereby eliminating the need to use surface or
coupling chemistries, which can alter the structure or function
of the protein being studied.
The native and variant proteins were titrated against their
known ligands. For both proteins, the T4L variant had a lower
ligand-binding affinity than the native receptor, but was still able
to bind the ligand (Fig. 6). Interestingly, the binding analyses
indicated that the T4L insert stabilized the receptor, even though it
also probably disrupted the ability of the receptor to bind its
ligand. Measurements taken on the same sample of hOR17-4T4L
over two months apart yielded the same results, while similar
measurements of hOR17-4 were noisier and less consistent.
Fig. 5 Circular dichroism spectra of native and T4L GPCRs. (A) hOR17-4 and hOR17-4T4L. (B) hVN1R1 and hVN1R1-T4L. The native and
T4L variants have alpha-helical secondary structures. However, the peaks are more pronounced in the T4L variants, suggesting that the structure
is more stabilized.
Fig. 6 Ligand binding measurements of native and T4L GPCRs. (A) hVN1R1 binding to myrtenal with an EC50 B 1 mM. (B) hVN1R1-T4L
binding to myrtenal with an EC50B 9 mM. (C) hOR17-4 binding to canthoxal with an EC50B 30 mM. (D) hOR17-4T4L binding to canthoxal with
an EC50B 70 mM. The native and T4L variants were able to bind their ligands, but the T4L variants had lower affinities. Boiled controls did not
bind their ligands, and had behavior similar to that observed in ref. 14 and 20. For clarity, they are not shown. All curves are normalized to the
fraction of bound receptor, and are fit to the Hill equation with a coefficient of 2. (A) is from ref. 14 and is shown here for comparison.
Pu
bl
ish
ed
 o
n 
15
 M
ar
ch
 2
01
2.
 D
ow
nl
oa
de
d 
by
 L
ud
w
ig
 M
ax
im
ili
an
s U
ni
ve
rs
ita
et
 M
ue
nc
he
n 
on
 1
1/
07
/2
01
3 
11
:0
9:
08
. 
View Article Online
1758 Mol. BioSyst., 2012, 8, 1750–1759 This journal is c The Royal Society of Chemistry 2012
Discussion
A significant challenge in the field of GPCR structural biology
lies in finding strategies that can be applied to multiple proteins.
Indeed, crystallization conditions for even similar or related
proteins are unique and must be empirically determined.32
Insertion of T4 lysozyme in the third intracellular loop of GPCRs
seems to be a promising approach, as 5 of the 7 structures to date
were obtained using this strategy.3–10 However, to be truly useful,
this approach should not only facilitate crystallization, it should
also not interfere with the normal structure and function of the
protein. Our study has examined how addition of the T4L
sequence in the third intracellular loop affects expression,
solubilization, purification, folding, and function of two olfactory
related GPCRs.
The detergent screens suggest that insertion of T4L could
alter the optimal detergent for the protein. The receptors
hVN1R1 and hVN1R1-T4L had similar patterns of solubility
in the tested detergents, while the solubility pattern of hOR17-4
and hOR17-4T4L was more variable. However, in both cases,
the optimal detergents for both native and fusion proteins
belonged to the same general class, and had similar structures
or chemical properties.
Results obtained during the purification process indicate
that insertion of T4L may help increase the yield of soluble
protein for crystallization screens. Size-exclusion chromatography
showed that B10–40% of the recovered native receptor was the
soluble monomer. In contrast, at least 50%, and up to 70%, of
the recovered fusion protein was the soluble monomer. This is an
important finding, because milligram quantities of homogeneous
protein are needed for crystallization trials and other structural
studies. Aggregation or impurities are common, and severely limit
the amount of usable protein typically obtained after a batch
purification. Indeed, up to 90% of the receptor obtained from the
native proteins was aggregated or impure, and could not be used
for subsequent experiments. Addition of T4L increased the yield
of usable receptor, likely due to its solubility, which increased the
solubility of the fusion protein. In addition, the CD and MST
measurements indicated that the T4L insert may help stabilize the
protein in which it is inserted; both T4L variants had more
defined CD spectra, and hOR17-4T4L was able to bind its ligand
2 months after it was purified. This is particularly important, as
several months may be needed for crystal growth.
Immunohistochemical data, calcium imaging assays, circular
dichroism, andmicroscale thermophoresis suggest that insertion of
T4L in the third intracellular loop does not completely disrupt
protein structure and function. Both T4L variants trafficked to the
cell membrane. Because membrane localization can be impaired
for improperly folded or glycosylated GPCRs, this suggests
that the T4L insertion does not adversely affect receptor
structure. Circular dichroism showed that the purified proteins
had alpha-helical conformations, suggesting that they were
properly folded. Indeed, the T4L variants had more defined
peaks, suggesting that they might be more stable. Ca2+
imaging assays in HEK293 cells demonstrated that signaling
still occurred with the hOR17-4T4L variant although it was
more limited. This is in stark contrast to the T4L variants of
non-olfactory receptors. Of the currently determined structures,
signaling assays in cells have only been performed on the
A2A adenosine and CXCR4 T4L fusion proteins.
5,6 In both
constructs, no downstream signaling was observed. This
difference is likely due to deletion of a greater portion of the
third intracellular loop in the non-olfactory GPCRs. It may
also be caused by the specific orientation of the T4L segment,
and the resulting stearic hindrance. Microscale thermophoresis
measurements of purified receptors showed that the T4L variants
had higher EC50 values, but were still able to bind their small
molecular ligands. Together, the Ca2+ imaging and MST results
suggest that the insert may interfere with G-protein interactions,
as well as with ligand binding. Since GPCRs are known to have
many flexible conformations, it is possible that the T4L insertion
may stabilize a particular conformation, making binding of
certain ligands more difficult. Thus, although lower binding
affinities were measured with canthoxal (hOR17-4) and myrtenal
(hVN1R1), it is possible that interactions with other ligands
would be less affected. Indeed, non-olfactory related GPCRs
sometimes exhibited higher affinities in the T4L constructs.5
Future experiments will be carried out to probe potentially
altered receptor coupling to G proteins, as well as changes in
second messenger signaling.33–35
Structural knowledge of GPCRs and other membrane
proteins is a prerequisite for the design of specific therapies
or biologically inspired sensing technologies. Insertion of T4
lysozyme in the third intracellular loop seems to be a promising
strategy for GPCR studies, as five of the seven crystallized
GPCRs have a T4L insertion. The results presented here further
support this. Furthermore, they open the possibility that T4L
insertion may facilitate structural studies of a wider range of
7TM proteins, and potentially other membrane proteins.
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